JP2024513972A5 - - Google Patents

Info

Publication number
JP2024513972A5
JP2024513972A5 JP2023562698A JP2023562698A JP2024513972A5 JP 2024513972 A5 JP2024513972 A5 JP 2024513972A5 JP 2023562698 A JP2023562698 A JP 2023562698A JP 2023562698 A JP2023562698 A JP 2023562698A JP 2024513972 A5 JP2024513972 A5 JP 2024513972A5
Authority
JP
Japan
Prior art keywords
nucleic acid
nucleotide
acid according
sense strand
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513972A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/024692 external-priority patent/WO2022221457A1/en
Publication of JP2024513972A publication Critical patent/JP2024513972A/ja
Publication of JP2024513972A5 publication Critical patent/JP2024513972A5/ja
Pending legal-status Critical Current

Links

JP2023562698A 2021-04-13 2022-04-13 Rnaサイレンシング剤および使用方法 Pending JP2024513972A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163174507P 2021-04-13 2021-04-13
US63/174,507 2021-04-13
PCT/US2022/024692 WO2022221457A1 (en) 2021-04-13 2022-04-13 Rna silencing agents and methods of use

Publications (2)

Publication Number Publication Date
JP2024513972A JP2024513972A (ja) 2024-03-27
JP2024513972A5 true JP2024513972A5 (cg-RX-API-DMAC7.html) 2025-04-09

Family

ID=83639690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562698A Pending JP2024513972A (ja) 2021-04-13 2022-04-13 Rnaサイレンシング剤および使用方法

Country Status (7)

Country Link
US (1) US20240191229A1 (cg-RX-API-DMAC7.html)
EP (1) EP4323376A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024513972A (cg-RX-API-DMAC7.html)
CN (1) CN117425664A (cg-RX-API-DMAC7.html)
AU (1) AU2022257002A1 (cg-RX-API-DMAC7.html)
CA (1) CA3216732A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022221457A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
US20240401045A1 (en) 2021-10-01 2024-12-05 Adarx Pharmaceuticals, Inc. Angiotensinogen-modulating compositions and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
KR20110110776A (ko) * 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
EP2264169A1 (en) * 2009-06-15 2010-12-22 Qiagen GmbH Modified siNA
JP6106085B2 (ja) * 2010-08-24 2017-03-29 サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. 内部非核酸スペーサーを含む一本鎖RNAi剤
KR101696704B1 (ko) * 2013-12-17 2017-01-16 주식회사 인코드젠 오프-타겟을 막기 위해 변형된 rna 간섭 유도 핵산 및 그 용도
EP3736334A1 (en) * 2014-07-16 2020-11-11 Arrowhead Pharmaceuticals, Inc. Rnai compositions to treat apoc3-related diseases
AU2015367378A1 (en) * 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing

Similar Documents

Publication Publication Date Title
JP2007529224A5 (cg-RX-API-DMAC7.html)
US5631135A (en) Oligonucleotide N3'→P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) Oligodeoxyribonucleotide N3' P5' phosphoramidates
CA2924186C (en) Highly efficient synthesis of long rna using reverse direction approach
US5965720A (en) Oligonucleotide N3'→P5' phosphoramidates
JP2022528840A5 (cg-RX-API-DMAC7.html)
JP2005524393A5 (cg-RX-API-DMAC7.html)
Sharma et al. Synthesis and biological properties of triazole-linked locked nucleic acid
JP2021503941A5 (cg-RX-API-DMAC7.html)
JPH07501527A (ja) 修飾されたピリミジンを含有するオリゴマーを使用する増強された三重らせんおよび二重らせんの成形
KR20260007576A (ko) 변형된 가이드 rna
RU2014121304A (ru) Ингибирование экспрессии вирусных генов
JP3653102B2 (ja) 末端3′−3′および/または5′−5′連鎖を有するオリゴリボヌクレオチドおよびリボザイム類縁体
JP2009524419A5 (cg-RX-API-DMAC7.html)
EP3137606A1 (en) METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT
HUT69981A (en) Self-stabilized oligonucleotides as therapeutic agents
JP2008283975A5 (cg-RX-API-DMAC7.html)
PL169576B1 (pl) Sposób wytwarzania czasteczki RNA o aktywnosci katalitycznej PL PL
JP2008500817A5 (ja) Dnaウイルスのマイクロrna及びそれを阻害する医薬品
Nurmi et al. A modified X10-23 DNAzyme that can better access large, structured RNA targets
TW202329983A (zh) Rna編輯
JP2024522272A5 (cg-RX-API-DMAC7.html)
CN117425664A (zh) Rna沉默剂及使用方法
Gotfredsen et al. Novel oligodeoxynucleotide analogues containing a 2′-O-methylarabinonucleoside
CA2106015A1 (en) Ribozymes having 2'-0 substituted nucleotides in the flanking sequences